Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 7/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 11/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 9/20 | 0.37 |
| ▸ | SUMO3 | P55854 | 1/20 | 0.32 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.32 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7097579 | 0.82 | MAPK10 (0.40) | MAPK10LCKMKNK1MKNK2 | |
| SCHEMBL7147806 | 0.79 | LCK (0.44) | MAPK10LCKMKNK1MKNK2SUMO3 | |
| SCHEMBL7100179 | 0.75 | MAPK10 (0.41) | MAPK10LCKMKNK1MKNK2SUMO3 | |
| SCHEMBL7152631 | 0.73 | LCK (0.40) | MAPK10LCKMKNK1MKNK2 | |
| SCHEMBL7148377 | 0.73 | TP53 (0.41) | MAPK10LCKMKNK1MKNK2 | |
| SCHEMBL7097114 | 0.72 | LCK (0.38) | MAPK10LCKMKNK1MKNK2SUMO3 | |
| SCHEMBL7147406 | 0.72 | MAPK13 (0.41) | MAPK10LCKMKNK1MKNK2 | |
| SCHEMBL7103831 | 0.71 | MKNK1 (0.41) | LCKMKNK1MKNK2 | |
| SCHEMBL7145870 | 0.71 | LCK (0.70) | LCKMKNK1MKNK2 | |
| SCHEMBL15886668 | 0.64 | MEN1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |
| EP-1194152-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1206260-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1206265-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1206260-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1194152-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6329380-B1 | PYRIMIDINE BENZIMIDIZAZOLE, PYRIMIDINEIMIDAZOLE OR PYRIDINE IMIDAZOLE COMPOUNDS FOR ANTICANCER AGENTS OR ATHEROSCLEROSIS | MERCK & CO., INC. | 2001-12-11 | — | — | US | disclosed |
| US-6316444-B1 | SRC kinase inhibitor compounds | MERCK & CO., INC. | 2001-11-13 | — | — | US | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000207-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000214-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |